Skip to main content
An official website of the United States government

anti-HLA-G/CD3 bispecific antibody RO7515629

A bispecific antibody targeting the tumor-associated antigen (TAA) histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody RO7515629 targets and binds to both CD3 on cytotoxic T lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor cell types and plays a key role in cancer immune evasion. It inhibits the immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T and B lymphocytes, and dendritic cells (DCs).
Synonym:anti-HLA-G T-cell engager RO7515629
CD3-binding T-cell engager RO7515629
HLA-G TCB RO7515629
HLA-G-TCB RG6353
T-cell bispecific antibody RO7515629
TCB RO7515629
TCE RO7515629
Code name:RG 6353
RG-6353
RG6353
RO 7515629
RO-7515629
RO7515629
Search NCI's Drug Dictionary